Hutchmed (HCM) news
Recent news
Hutchmed trial shows pfs benefit in met+ EGFR-mutated lung ca
AInvest Wire · 9h agoH Hutchmed (China) - Fanregatinib to be marketed in China as Atled
Hutchmed (China) has announced that Fanregatinib, a targeted therapy, has been approved for marketing in China under the brand name Atled. This approval marks a significant milestone for the company, reflecting regulatory confidence in the drug's safety and efficacy profile. The National Medical…
AInvest Wire · 3d agoH Hutchmed Chin: NMPA approval for Atled Fanregratinib for ICC
AInvest Wire · 3d agoHutchmed (China) - Announces NMPA conditional approval for Atled (Fante gratinib) in China
Hutchmed (China) has announced that the National Medical Products Administration (NMPA) has granted conditional approval for Atled (fentigratinib) in China. This approval marks a significant milestone for the company, as it expands the availability of targeted treatment options for patients with…
AInvest Wire · 3d agoHutchmed (China) Ltd: insolvency proceedings remain ongoing, outcome of proceedings is not known to company as at date of this announcement
Hutchmed (China) Ltd has confirmed that insolvency proceedings remain ongoing, with the outcome of these proceedings currently unknown to the company as of the date of the announcement. The company has not disclosed further details regarding the nature or timeline of the proceedings, nor has it…
AInvest Wire · Aug 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.